{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:44:38Z","timestamp":1793684678842,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaccao.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T16:28:42Z","timestamp":1602001722000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Immune Checkpoint Inhibitor Therapy Aggravates T Cell\u2013Driven Plaque Inflammation in Atherosclerosis"],"prefix":"10.1016","volume":"2","author":[{"given":"Kikkie","family":"Poels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy M.T.","family":"van Leent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu E.","family":"Meerwaldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohana C.A.","family":"Toner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe E.","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal J.H.","family":"Kusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsveta","family":"Malinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Huveneers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey E.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi A.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno P.J.","family":"de Winther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J.M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.P.","family":"Seijkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Lutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2020.08.007_bib1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced\u00a0melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fphys.2012.00018","article-title":"T\u00a0cell costimulatory and coinhibitory pathways in vascular inflammatory diseases","volume":"3","author":"Lichtman","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccell.2019.11.005","article-title":"One or two immune checkpoint inhibitors?","volume":"36","author":"Robert","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2020.08.007_bib9","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jaccao.2020.08.007_bib10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib12","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MOL.0000000000000538","article-title":"Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis","volume":"29","author":"Seijkens","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib14","article-title":"Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease","volume":"8","author":"Lutgens","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2020.08.007_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41572-019-0116-x","volume":"5","author":"Libby","year":"2019","journal-title":"Atherosclerosis. Nat Rev Dis Primers"},{"key":"10.1016\/j.jaccao.2020.08.007_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjms.2018.11.017","article-title":"Hepatotoxicity and recurrent NSTEMI while on pembrolizumab for metastatic giant cell bone tumor","volume":"357","author":"Kwan","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaccao.2020.08.007_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2020.08.007_bib18","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/annonc\/mdx326","article-title":"Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody","volume":"28","author":"Tomita","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10554-014-0370-7","article-title":"Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study","volume":"30","author":"Mani","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2020.08.007_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2020.08.007_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","article-title":"Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis","volume":"71","author":"Seijkens","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/eurheartj\/ehy714","article-title":"Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death","volume":"40","author":"Seijkens","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2020.08.007_bib23","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2020.08.007_bib24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.112.001347","article-title":"Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice","volume":"127","author":"Kyaw","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2020.08.007_bib25","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 Control of T-cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib26","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1073\/pnas.0910341107","article-title":"Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2020.08.007_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.jaccao.2020.08.007_bib28","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1172\/JCI61931","article-title":"Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects","volume":"122","author":"Ruocco","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2020.08.007_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093280","article-title":"Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. Ashour HM, editor","volume":"9","author":"Cochain","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2020.08.007_bib32","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2020.08.007_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cvr\/cvx248","article-title":"Exploring immune checkpoints as potential therapeutic targets in atherosclerosis","volume":"114","author":"Kusters","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2020.08.007_bib34","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jacc.2006.05.076","article-title":"In\u00a0vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients","volume":"48","author":"Tawakol","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib35","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1161\/01.CIR.0000020548.60110.76","article-title":"Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography","volume":"105","author":"Rudd","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2020.08.007_bib36","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.jacc.2009.12.061","article-title":"Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time?","volume":"55","author":"Rudd","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib37","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jaccao.2020.08.007_bib38","doi-asserted-by":"crossref","first-page":"107148","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jaccao.2020.08.007_bib39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5551\/jat.RV17027","article-title":"Mechanism and management of cancer chemotherapy-induced atherosclerosis","volume":"25","author":"Mukai","year":"2018","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jaccao.2020.08.007_bib40","article-title":"Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease","volume":"8","author":"Lutgens","year":"2020","journal-title":"Immunother Cancer"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732030212X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732030212X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:53:08Z","timestamp":1762973588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608732030212X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S266608732030212X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.007","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor Therapy Aggravates T Cell\u2013Driven Plaque Inflammation in Atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}